Alliance Global Partners Initiates Coverage on INmune Bio (NASDAQ:INMB)

Research analysts at Alliance Global Partners began coverage on shares of INmune Bio (NASDAQ:INMB) in a research report issued on Monday, Benzinga reports. The firm set a “buy” rating and a $20.00 price target on the stock. Alliance Global Partners’ price target would indicate a potential upside of 291.39% from the stock’s previous close.

A number of other analysts also recently issued reports on the stock. Scotiabank started coverage on shares of INmune Bio in a report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective on the stock. Raymond James began coverage on shares of INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target on the stock.

INmune Bio Trading Up 2.2 %

INMB opened at $5.11 on Monday. The firm’s fifty day simple moving average is $5.89 and its 200 day simple moving average is $8.09. The stock has a market capitalization of $101.09 million, a P/E ratio of -2.66 and a beta of 1.85. INmune Bio has a 12 month low of $4.78 and a 12 month high of $14.74.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. On average, equities research analysts predict that INmune Bio will post -2.14 EPS for the current fiscal year.

Insider Buying and Selling at INmune Bio

In related news, CFO David J. Moss acquired 10,000 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were bought at an average price of $5.29 per share, for a total transaction of $52,900.00. Following the purchase, the chief financial officer now directly owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO David J. Moss bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The stock was acquired at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the purchase, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at approximately $6,802,247.01. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO David J. Moss purchased 7,690 shares of the stock in a transaction on Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the transaction, the chief financial officer now owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 33,070 shares of company stock worth $200,087 over the last ninety days. 35.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On INmune Bio

A number of large investors have recently added to or reduced their stakes in INMB. Fermata Advisors LLC boosted its position in INmune Bio by 6.9% during the first quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock worth $370,000 after purchasing an additional 2,025 shares during the period. Westside Investment Management Inc. lifted its stake in shares of INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after buying an additional 10,950 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after buying an additional 32,511 shares during the period. Rhumbline Advisers acquired a new position in INmune Bio in the 2nd quarter valued at about $121,000. Finally, Marshall Wace LLP grew its stake in INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after buying an additional 89,091 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.